Health Update

In This Issue:

  • Ten Years In: Charting the Progress of Health Information Exchange in the U.S.

  • How the ACA Is Changing the Management of Patient and Healthcare Data

  • Medicare Part D Proposed Rule: Where Did Things Go Wrong?

  • New, Free Webinar from Manatt Health and Bloomberg BNA: “The Evolution of Health IT and EHRs”

  • Much Critical ACA Guidance Is Just Emerging. How Can You Be Ready for the Major Changes Still Ahead?

Ten Years In: Charting the Progress of Health Information Exchange in the U.S.

Authors: William Bernstein, Partner, Chair, Healthcare Division, Manatt, Phelps & Phillips, LLP | Helen Pfister, Partner, Healthcare Industry, Manatt, Phelps & Phillips, LLP | Susan Ingargiola, Director, Manatt Health Solutions

Editor’s Note: Efforts to digitize the U.S. healthcare system and make it possible to exchange health information electronically have been underway for more than a decade. Manatt Health has created a new report for the California Healthcare Foundation taking stock of the nation’s health information exchange (HIE) progress and summarizing the opportunities and challenges that lie ahead. The report describes the HIE landscape as it stands today, nearly 10 years after the creation of the Office of the National Coordinator (ONC) and 5 years after the passage of the Health Information Technology for Economic and Clinical Health Act (HITECH). It assesses the nation’s HIE efforts in three areas: electronic health record (EHR) adoption; standards, certification and incentives for HIE; and governance. Below is a summary of key highlights. Click to download the full report.

HITECH: Federal Dollars Spur Adoption and Use

The modern era of HIE-related public policy began in May 2004 with the appointment of the first national coordinator for HIT and the release of the federal government’s first comprehensive HIT strategy document. At that time, however, federal support for HIT did not have significant funding and therefore focused primarily on the private sector.

In 2009, Congress passed HITECH as part of the American Recovery and Reinvestment Act. HITECH’s cornerstone was the Medicare and Medicaid EHR Incentive Programs, which provide hospitals and professionals with financial incentives for the “meaningful use” of EHR technology to improve patient care. In 2015, the Medicare program will transition from offering incentives to imposing penalties on those not meaningfully using EHRs.

The U.S. Department of Health and Human Services (HHS) originally envisioned that the Meaningful Use Incentive Programs would evolve through three stages over five years. In December 2013, however, it proposed to extend the timeline by two years. Stage 1 focuses on EHR adoption, basic electronic data capture and medication ordering. Future stages require providers to use EHRs for exchanging health information and improving care, efficiency and population health. In addition to establishing the EHR Incentive Programs, HITECH allocated more than $2 billion for HIT and HIE infrastructure development.

EHR Adoption Rate Growth and Gaps

The adoption of EHRs has increased dramatically since HITECH was implemented in 2010. Adoption rate highlights include:

  • 44% of hospitals had adopted EHRs in 2012, up from just 17% in 2011.

  • As of February 2014, HITECH’s Regional Extension Center (REC) program has worked with nearly half of the nation’s primary care providers, helping 90% of those adopt EHRs and 62% demonstrate stage 1 meaningful use.

  • According to the 2013 National Ambulatory Medical Care Survey, nearly 80% of office-based physicians report using an EHR system.

  • As of December 2013, the Medicare and Medicaid EHR Incentive Programs had paid almost $19 billion to 335,000 professionals and 4,400 hospitals.

Despite the widespread increase in EHR adoption, serious gaps remain. Providers in rural and low-income areas, as well as long-term care and behavioral health providers, have lower adoption rates than the general provider population.

Concerns Around the Meaningful Use Program

While most agree meaningful use has been an effective policy lever in Stage 1, some believe it could impede further EHR adoption. Concerns include:

  • Stage 2 may be moving too quickly and be too complex in its requirements.

  • Meaningful use may prevent providers from using EHRs to their full potential by putting completing the program’s steps before improving health outcomes.

  • There are too many meaningful use measures that are too tactically focused.

  • The role of EHRs in care coordination and analytics is being overemphasized.

Standards and Certification—Federal Government Efforts

As it was 10 years ago, achieving interoperability—the ability of two healthcare providers to exchange data and present it in an understandable manner to patients—continues to be an important HIT goal. Despite the inclusion of standards in the meaningful use program, however, the healthcare system has yet to achieve interoperability. The current federal strategy for developing and adopting HIE standards is articulated in a June 2013 report to Congress from ONC. According to the report, ONC’s approach includes:

  • Supporting flexible, incremental and modular standards.

  • Selecting standards that work for the future.

  • Making incremental changes with community feedback.

  • Supporting implementation and precertification testing.

Standards and Certification—Private and State-Based Efforts

State and private sector players have contributed to standards development. In February 2011, 19 states and 43 EHR/HIE vendors formed the EHR Interoperability Workgroup, which released its first set of functional, technical and test specifications in 2013.

In March 2013, a coalition of EHR vendors formed the CommonWell Health Alliance to address the problem of interoperability. The alliance will initially certify core interoperability services and standards for vendors to embed in their software. The services the alliance will test in its 18- to 24-month proof-of-concept phase include:

  • Cross-identity management services—identifying patients as they move among settings, regardless of the underlying software.

  • Patient consent and data access management—providing a HIPAA-compliant, patient-controlled way to simplify managing consents and authorizing data sharing.

  • Patient record location and directed query services—delivering a history of recent patient encounters and, with the right authorization, patient data across multiple providers and care episodes.

HIE Incentives and Payment Reform

In addition to requiring compliance with technological standards, the federal government has sought to encourage HIE through payment incentives, beginning with meaningful use requirements and now including the payment reform provisions of the ACA. Experts agree, however, that widespread HIE won’t occur until new payment approaches, such as bundled payment options, accountable care organizations (ACOs) and medical home initiatives, create the case for information exchange. According to many experts, HITECH was meant to be coupled with ACA-style payment reform provisions.

The ACA includes a series of new payment and delivery system initiatives that, in some measure, require better HIT systems. For example, to function successfully, ACOs need timely access to performance metrics, patient events and patient status information. The proliferation of ACOs is a contributing factor to large health systems’ desire to build or procure their own HIEs. State efforts to redesign their Medicaid programs to reward more efficient and coordinated care also are drivers of HIE.

HIE Governance

HIE governance refers to the establishment and oversight of common behaviors, policies and standards that enable trusted HIE among a set of participants. While the need for governance is widely recognized, the last 10 years have not brought a consensus on the nature or extent to which governance is required at the national, state, regional or community levels.

There have been several efforts at the national level to establish HIE governance, none of which have been successful. With the passage of HITECH, Congress required ONC to establish a governance mechanism for the Nationwide Health Information Network (NHIN). Public feedback, however, indicated that market conditions were not right. Therefore, ONC decided instead to define general principles for supporting HIE. In May 2013, ONC released the “Governance Framework for Trusted Electronic Health Exchange” outlining four categories of principles for HIE governance:

  • Trust principles provide guidance on patient privacy, meaningful choice and data management.

  • Business principles focus on responsible financial and operational policies, emphasizing transparency and patients’ best interests.

  • Technical principles prioritize standards to support trust and business principles, as well as to further interoperability.

  • Organizational principles identify approaches for good governance.

In addition to national efforts, there have been a number of state-level HIE governance initiatives. One major effort was the 2009 launch of the State Health Information Exchange Cooperative Agreement Program. Through this program, ONC provided $564 million in HITECH funds to states and state-designated entities for developing plans that address statewide policy, governance, technical infrastructure and business practices in support of HIE.

ONC’s support is winding down as funding was from 2010 through 2013. The future of state initiatives will rest on whether stakeholders decide to provide continued financial support.


Nearly a decade after the establishment of the ONC and five years after the passage of HITECH, the U.S. is progressing with harnessing the power of health information to support more cost-effective and higher-quality care. The combination of government initiatives and market forces is propelling the nation forward to a time when creating, sharing and using electronic information to improve healthcare decision making and management will be commonplace.

How the ACA Is Changing the Management of Patient and Healthcare Data

Author: Jonah Frohlich, Managing Director, Manatt Health Solutions

Editor’s Note: In the February issue of PharmaVoice, Manatt Health examines how the ACA is driving faster transformation of the healthcare delivery system. Key points are summarized below. Click to download the full article.

The ACA is accelerating a reorganization of the healthcare delivery system from episodic, reactive, acute management of patients to proactive, population-based delivery models. This transformation requires both payers and providers to manage high-risk patients and chronic diseases aggressively, identify risk factors and engage patients in self-management. All of these tasks demand accurate, timely, secure information, available to both patients and providers. Organizations able to manage the heavy flow of information needed to optimize health outcomes, contain costs and support high-needs patients while keeping less complex patients healthy will gain more market share.

The Importance of Data Convergence

Current medical record systems do a good job of digitizing health data, and their adoption has been rapid. The number of hospitals using electronic health records soared from 9.4% in 2008 to 44.4% in 2012.

Other tools are needed, however, to support population-based care delivery models. Registries, analytics and business intelligence systems are being deployed to:

  • Identify high-risk populations,

  • Apply protocols for prompting patient outreach,

  • Assess treatment pathways,

  • Report measures internally and externally to inform decision making, and

  • Demonstrate value to health plans and purchasers.

Effective implementation across all of these applications requires a convergence of clinical, financial and utilization data into a single data stream that can be mined across the delivery spectrum. That integration, however, demands trust among the participants—and a rationale for sharing their information with other players. With its regulatory changes and focus on financial alignment, the ACA is providing that rationale, giving healthcare stakeholders incentives for collaborating to improve outcomes and limit costs.

Data Standards and Governance

To automate integration so data can become an actionable part of the healthcare planning and delivery processes requires addressing two key areas—data standards and data governance:

  • The slow pace of developing interoperability standards remains a hurdle to the seamless integration and exchange of data. Moving forward demands the faster and broader adoption of specifications and systems that can handle extracting, translating and loading large data sets from a variety of sources into a normalized data repository.

  • Accessing and integrating data effectively require a full understanding of the laws and practices governing its use. Organizations that know the rules and have robust privacy and security policies will be better prepared to manage the flood of information from all of their partners.

The Shift from Volume to Value

As health reform moves forward, we are seeing a shift in the focus of our regulatory, delivery and payment systems from volume to value. This new perspective will mean changes for both providers and product suppliers, including the need to:

  • Become successful risk-bearing organizations.

  • Demonstrate the real value of their products, in lowering costs and improving outcomes for complex patients, as well as in increasing the chances of keeping less-acute patients healthy and out of expensive treatment settings.

  • Support a value-based purchasing strategy.

Organizations that effectively navigate these changes will allow more of their products to be integrated into the benefits packages provided on exchanges.

Medicare Part D Proposed Rule: Where Did Things Go Wrong?

Author: Ian Spatz, Senior Advisor, Healthcare Industry, Manatt Health Solutions

Editor’s Note: In a recent Health Affairs blog post, Ian Spatz analyzes the widespread pushback against the Medicare Part D proposed rule. Highlights are summarized below. Click here to read the full post.

On January 10, the Centers for Medicare and Medicaid Services (CMS) published a Medicare Part D proposed rule that set off a firestorm of dissent. Fundamentally, CMS has suggested some major changes to the decade-old Medicare prescription drug program that further inserts itself into directing the terms of competition in Part D.

The CMS proposed rule has united a disparate group of interests who, while not agreeing on much else, do agree they want the proposal to go away. For example, on February 28, 277 organizations (with more continuing to join)—including patient advocates, insurance companies, health plans, employers and both brand and generic drug companies—signed a letter slamming the proposed rule. Following that, 20 of the 24 members of the Senate Finance Committee wrote CMS Administrator Marilyn Tavenner, urging her to scrap the plan.

What’s Causing the Controversy?

While some may like parts of the proposed rule, as a whole, many believe the status quo is better than the Part D future Medicaid has presented. Some key areas of controversy include:

  • Introducing new criteria for protected drug classes. From the start of Part D, CMS believed there were certain conditions for which patients and physicians needed immediate access to a broad choice of medicines that might not be available if a Part D plan excluded them from its formulary. CMS is now suggesting criteria for whether a class of drug would need this protection. The result is that two of the six protected classes, antidepressants and immunosuppressants, would lose their protection immediately, and antipsychotics might lose it in a year. While Part D plans support this result because of potential cost savings, drug companies and some beneficiary groups are concerned that patients and caregivers won’t know how to navigate the process of appealing a drug coverage denial.

  • Expanding medication therapy management. Part D requires plans to provide extra medication counseling and coordination to beneficiaries with multiple chronic conditions and high drug costs. CMS is planning to expand that requirement significantly. Pharmacy groups are cheering the move, but plans question the value of the added costs.

  • Limiting plan offerings. CMS has proposed a series of changes that would limit the number and kind of plans offered under Part D. One change would limit of the use of preferred pharmacy networks. Plan sponsors oppose the change, claiming limited networks lower premiums and cost sharing for beneficiaries, while CMS is concerned they actually increase costs. Another change limits the number of plans offered in a region, with CMS asserting that too many choices with too little differentiation causes confusion. Opponents don’t understand why CMS would take choices away, asserting that beneficiaries are able to pick the plan that’s right for them.

  • Breaching the principle of noninterference in drug pricing. In its proposed rule, CMS surprised everyone by stating that it needed to define the limits of its powers related to drug pricing. Its proposed language has alarmed Part D plans and provided little comfort to drug companies.


Each of these issues and more have inflamed groups with strong interest in Part D. While not all agree on every issue, the powerful pushback indicates that now may not be the right time to rock the Part D boat.

New, Free Webinar from Manatt Health and Bloomberg BNA: “The Evolution of Health IT and EHRs”

Click here and Enter Code LGAUEXT5 to Register Free and Earn CLE.

Join Manatt Health and Bloomberg BNA at a new, free webinar, “The Evolution of Health IT and EHRs: Setting the Stage for Growth and Value.” The webinar details the emergence of health IT, focusing primarily on developments over the last decade that have accelerated the adoption and use of electronic health records (EHRs). The program will begin by providing a framework for understanding health IT, tracking its growth from its inception through the IOM (Institute of Medicine) to its implementation through HITECH (Health Information Technology for Economic and Clinical Health Act).

The session will provide definitions of key concepts and terms, deciphering the alphabet soup of acronyms around health IT. It also will share insights into the role that federal and state governments play in accelerating, coordinating and overseeing health IT.

In addition, the webinar will give participants an in-depth look at the benefits EHRs deliver, including how they increase the efficiency, effectiveness, quality and safety of care. The program will track the market and policy changes that have supported the adoption of EHRs, including a detailed assessment of the federal initiative for supporting their meaningful use. In addition, it will explore the impact of EHRs on medical practice—and offer a practical discussion of the legal liabilities and risks associated with EHR use. Attendees will gain valuable insights into:

  • The evolution and growth of health information technology over the past 10 years, detailing key reports, programs, legislation and milestones.

  • The key concepts and terms around the electronic capture, transmission, exchange and use of health information.

  • Governmental coordination of health IT, including federal leadership and oversight, the roles that states play and the guidelines for public/private partnerships.

  • The value and benefits of EHRs.

  • Government actions to accelerate adoption, including actions to remove regulatory barriers and support implementation.

  • The meaningful use of EHRs, delving into the full range of requirements, incentives and penalties.

  • The effects EHRs will have on medical practice, including potential EHR-related errors; federal efforts to address EHR safety; and EHR use, legal liabilities and risks.

Click here and enter code LGAUEXT5 to register free. 


William Bernstein, Partner, Chairman, Healthcare Division, Manatt, Phelps & Phillips, LLP

Jonah Frohlich, Managing Director, Manatt Health Solutions

Anne O. Karl, Associate, Healthcare Industry, Manatt, Phelps & Phillips, LLP

Much Critical ACA Guidance Is Just Emerging. How Can You Be Ready for the Major Changes Still Ahead?

As the Affordable Care Act (ACA) moves into full implementation, it is dramatically changing the nation’s healthcare landscape. Although we’ve come a long way in defining the specifics of our healthcare transformation since the ACA’s passage, many critical details are just now emerging in upcoming federal regulations and policy guidance. These new rules will require that all healthcare stakeholders rethink how they manage their organizations and structure their business relationships.

To help our clients navigate this volatile healthcare environment, Manatt Health began a series of analyses in 2013, fully explaining each guidance and its implications. The analyses provide concise, informative summaries, including relevant timelines, operational details and responsibilities, so you can respond effectively. With so many important changes still ahead, clients have requested that we continue delivering these important tools in 2014.

To meet this demand, we will provide an ACA Guidance Package for 2014, covering all new guidance issued over the coming year. (Click for a list of anticipated guidance.) The Package includes:

  • All Medicaid Guidance Summaries

  • All Insurance Guidance Summaries

Plus, new this year, we also will send you the new Bloomberg BNA portfolio, “Affordable Care Act Implementation: Regulations, Models and Implications,” authored by the health reform thought leaders at Manatt Health. Based on our deep experience with the ACA, Bloomberg BNA selected Manatt to “write the book” on healthcare reform, creating a practical guide to the complex statutes and regulatory requirements shaping our new healthcare system, as well as sharing key implementation considerations. Complete with hands-on practice tools, the portfolio offers a detailed discussion of every aspect of reform, from private insurance to Medicaid expansion to Marketplace models to certification standards to market reforms and mandates.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Manatt, Phelps & Phillips, LLP | Attorney Advertising

Written by:

Manatt, Phelps & Phillips, LLP

Manatt, Phelps & Phillips, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.